Accepted Articles                   Back to the articles list | Back to browse issues page

XML Print

1- Nutrition and Dietetics, Faculty of Health Sciences, Üsküdar University, Istanbul, Turkey.
2- Physiology, School of Medicine, Koç University, Istanbul, Turkey.
3- Molecular Neuroscience, Health Sciences Institute, Üsküdar University, Istanbul, Turkey.
4- Software Engineering, Faculty of Engineering and Natural Sciences, Üsküdar University, Istanbul, Turkey.
5- Psychiatry, School of Medicine, Üskudar University, Istanbul, Turkey.
Introduction: Parkinson's disease is the world's second most prevalent neurological disease. In Parkinson’s disease intracytoplasmic neuronal inclusions are observed in enteric neurons in the gastrointestinal tract, and the composition of the intestinal microbiome is altered. These changes correlate with the motor phenotype. A systematic review was conducted to determine the effect of probiotics with individuals with Parkinson’s disease.
Methods: Scopus, PubMed, Web of Science, The Cochrane Library, Science Direct and OVID-LWW were searched until April 2021 and total 27.395 records were reached according to inclusion and exclusion criteria with the following outcomes: Parkinson's disease rating; oxidative stress, and gastrointestinal system markers. Data searches, article selection and data extraction assessments were performed according to the PRISMA guidelines. The Jadad scale was used to rate the evidence's quality.
Results: The information gathered from 5 randomized controlled trials involving 350 individuals with Parkinson’s disease receiving probiotic supplements. Parkinson’s disease rating and non-motor symptoms test were performed. Oxidative stress (Glutathione, malondialdehyde) and gastrointestinal system symptoms (bowel opening frequency, gut transit time, complete bowel movement, spontaneous bowel movements) were evaulated for 4-12 weeks of usage.
Conclusion: While all high-quality studies demonstrate progress, there is currently insufficient data to recommend the use of probiotics for people with Parkinson's disease in clinical practice.
Type of Study: Review | Subject: Clinical Neuroscience
Received: 2021/08/26 | Accepted: 2021/10/9

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Basic and Clinical Neuroscience

Designed & Developed by : Yektaweb